AG0013YY

137862-53-4 | L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-

AG0013YY

SDS

COA

Price

$0.00

Add to Cart

Buy Now

WARNING This product is not for human or veterinary use.

CAS Number	137862-53-4
Catalog Number	AG0013YY(AGN-PC-0PLRSI)
Chemical Name	L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
EC Number	604-045-2
IUPAC Name	(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
InChI	InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1
InChI Key	ACWBQPMHZXGDFX-QFIPXVFZSA-N
MDL Number	MFCD00865840
Molecular Formula	C24H29N5O3
Molecular Weight	435.5188
NSC Number	758927
SMILES	CC(C)[C@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C(O)=O
UNII	80M03YXJ7I
Synonyms	48933, CGP, CGP 48933, Diovan, Kalpress, Miten, N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine, Nisis, Provas, Tareg, Vals, valsartan, valsartan, 137862-53-4, Diovan, Tareg, Provas, CGP 48933, L-Valsartan, CGP-48933, Exforge, (S)-2-(N-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid, UNII-80M03YXJ7I, MFCD00865840, N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, CHEMBL1069, 80M03YXJ7I, CHEBI:9927, C24H29N5O3, (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine, 137863-60-6, Kalpress, Miten, Nisis, Vals, (S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine, L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, N-[p-(o-1H-Tetrazol-5-ylphenyl)benzyl]-N-valeryl-L-valine, Valsarran, Valzaar, Valtan, Valsartan [USAN:INN], [3H]valsartan, (s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid, L-Valine, N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, SMR000466318, Diovan (TN), N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine, Prexxartan, Valpression, Varexan, HSDB 7519, L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, Valsartan [USAN:USP:INN:BAN], Valsartan,(S), (2S)-3-Methyl-2-(pentanoyl-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)amino)butanoic acid, (2S)-3-methyl-2-[pentanoyl-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid, AK-58790, valsartan (Diovan), PubChem9865, Spectrum_001796, AC1Q5QIK, N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine, Spectrum2_001120, Spectrum3_001831, Spectrum4_000749, Spectrum5_001582, Prexxartan (oral solution), EC 604-045-2, AC1L1U1M, SCHEMBL2542, BSPBio_003501, GTPL593, KBioGR_001078, KBioSS_002289, MLS000759423, MLS001424088, BIDD:GT0345, SPECTRUM1505209, SPBio_001260, GTPL3937, Valsartan (JP17/USAN/INN), Valsartan, >=98% (HPLC), KBio2_002287, KBio2_004855, KBio2_007423, KBio3_003006, KS-00000ISS, EZR-104, VAL-489, ACWBQPMHZXGDFX-QFIPXVFZSA-N, HMS1922L21, HMS2051L12, HMS2093K22, HMS2232F05, HMS3651E04, HMS3715P12, Pharmakon1600-01505209, ACT02671, BCP05184, ZINC3875259, ANW-49040, BDBM50049186, BG0645, GP8514, NSC758927, s1894, AKOS015914315, AKOS015994698, AB07510, AC-4543, AM90287, AN-7255, CCG-101028, CCG-221275, CS-1967, DB00177, DS-1248, KS-1194, MCULE-6728882368, NC00278, NSC-758927, RTR-031794, VA11929, N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine, BC204156, BR-58790, CPD000466318, HY-18204, I997, SAM001246581, SC-00971, SBI-0206738.P001, AB0013966, AB2000354, AX8018200, LS-161334, ST2408288, TL8000869, TR-031794, FT-0631156, SW197658-2, V-120, 4997-EP2270011A1, 4997-EP2272841A1, 4997-EP2277879A1, 4997-EP2295406A1, 4997-EP2295422A2, 4997-EP2298772A1, 4997-EP2298776A1, 4997-EP2298779A1, 4997-EP2301923A1, 4997-EP2301931A1, 4997-EP2301936A1, 4997-EP2305219A1, 4997-EP2308562A2, 4997-EP2308839A1, 62V534, D00400, J10013, S-6418, AB00639940-06, AB00639940-08, AB00639940_09, AB00639940_11, SR-05000001928, J-007068, SR-05000001928-1, BRD-K45158365-001-02-3, BRD-K45158365-001-05-6, I14-41498, Valsartan, European Pharmacopoeia (EP) Reference Standard, N-Valeryl-N-[2'-(5-tetrazolyl)biphenyl-4-ylmethyl]-L-valine, Valsartan, United States Pharmacopeia (USP) Reference Standard, N-Valeryl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-L-valine, Valsartan, Pharmaceutical Secondary Standard; Certified Reference Material, (5)-2-{N-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]pentanamido}-3-methylbutanoic acid, (S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, 3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-yl]-amino}-butyric acid, L-Valine,N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]methyl]- (9CI), N-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine, N-(1-oxopentyl)-N-[[2'-(1h-tetrazol-5-yl) [1,1'-bi-phenyl]-4-yl]methyl]-l-valine, N-(1-Oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(L)-valine, N-(1-OXOPENTYL)-N-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-L-VALINE, N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl}-L-valine, Valsartan for peak identification, European Pharmacopoeia (EP) Reference Standard, Valsartan for system suitability, European Pharmacopoeia (EP) Reference Standard, (2S)-3-methyl-2-[N-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid, (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid, (2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid., (2S)-3-Methyl-2-{N-pentanoyl-N'-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butanoic acid, (2S)-3-Methyl-2-{pentanoyl-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (s)-3-methyl-2-[N-({4-[2-(2h-1,2,3,4-tetrazol-5-yl) phenyl]phenyl}methyl)pentanamido]butanoic acid, (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid, (s)-3-methyl-2-{pentanoyl-[-2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (S)-3-Methyl-2-{pentanoyl-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (S)-3-Methyl-2-{pentanoyl-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, (S)-N-(1-carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine, (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine, 2-{[2''-(2,3-Dihydro-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-pentanoyl-amino}-3-methyl-butyric acid, 3-Methyl-2-{((S)-pentanoyl)-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amino}-butyric acid, walsartan, cardopan, valsartanin, Diovan Hct, Mixture Name, Diovan, Valsartan, Valzaar (TN), Valtan (TN), CEPA brand of valsartan, Lacer brand of valsartan, Sanol brand of valsartan, Esteve brand of valsartan, Aventis brand of valsartan, Schwarz brand of valsartan, Novartis brand of valsartan, D04HSR, D06UDG, Valsartan (JAN/USAN/INN), CID60846, C24-H29-N5-O3, 48933, CGP, CB10988, CS-O-10218, B2214, V0112, C081489, D000068756, 137862-87-4, L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-(9CI), Valsartan, 99%, a nonpeptide angiotensin II AT1 receptor antagonist - 250MG 250mg, (2S)-3-Methyl-2-(N-((2'-(1H-1,2,3,4-tetrazol-5-yl)-(1,1-biphenyl)-4-yl)methyl)pentanamido)butanoic acid, (R)-2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid, (S)-2-(N-((2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-methylbutanoic acid,

Complexity	608
Compound Is Canonicalized	Yes
Covalently-Bonded Unit Count	1
Defined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Exact Mass	435.227g/mol
Formal Charge	0
Heavy Atom Count	32
Hydrogen Bond Acceptor Count	6
Hydrogen Bond Donor Count	2
Isotope Atom Count	0
Molecular Weight	435.528g/mol
Monoisotopic Mass	435.227g/mol
Rotatable Bond Count	10
Topological Polar Surface Area	112A^2
Undefined Atom Stereocenter Count	0
Undefined Bond Stereocenter Count	0
XLogP3	4.4

GHS Hazard and Precautionary Statements

Symbol:
Hazard Class
Hazard statements	H302+H312+H332-H315-H319-H335
Packing Group
Precautionary statements	P261-P280-P305+P351+P338
UN Code

Certificate of Analysis

Lot Number